These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 26671082)
1. Demonstration of equivalence of a generic glatiramer acetate (Glatopa™). Anderson J; Bell C; Bishop J; Capila I; Ganguly T; Glajch J; Iyer M; Kaundinya G; Lansing J; Pradines J; Prescott J; Cohen BA; Kantor D; Sachleben R J Neurol Sci; 2015 Dec; 359(1-2):24-34. PubMed ID: 26671082 [TBL] [Abstract][Full Text] [Related]
2. Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate. D Alessandro J; Garofalo K; Zhao G; Honan C; Duffner J; Capila I; Fier I; Kaundinya G; Kantor D; Ganguly T CNS Neurol Disord Drug Targets; 2017; 16(6):714-723. PubMed ID: 28240190 [TBL] [Abstract][Full Text] [Related]
3. Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis. Bell C; Anderson J; Ganguly T; Prescott J; Capila I; Lansing JC; Sachleben R; Iyer M; Fier I; Roach J; Storey K; Miller P; Hall S; Kantor D; Greenberg BM; Nair K; Glajch J J Pharm Pract; 2018 Oct; 31(5):481-488. PubMed ID: 28847230 [TBL] [Abstract][Full Text] [Related]
4. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial. Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F; JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034 [TBL] [Abstract][Full Text] [Related]
5. Two decades of glatiramer acetate: From initial discovery to the current development of generics. Weinstock-Guttman B; Nair KV; Glajch JL; Ganguly TC; Kantor D J Neurol Sci; 2017 May; 376():255-259. PubMed ID: 28431621 [TBL] [Abstract][Full Text] [Related]
10. Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition. Hasson T; Kolitz S; Towfic F; Laifenfeld D; Bakshi S; Beriozkin O; Shacham-Abramson M; Timan B; Fowler KD; Birnberg T; Konya A; Komlosh A; Ladkani D; Hayden MR; Zeskind B; Grossman I J Neuroimmunol; 2016 Jan; 290():84-95. PubMed ID: 26711576 [TBL] [Abstract][Full Text] [Related]
11. Multiple sclerosis relapse rates and healthcare costs of two versions of glatiramer acetate. Greenberg B; Hall S; Grabner M; Balu S; Zhang X; Kantor D Curr Med Res Opin; 2020 Jul; 36(7):1167-1175. PubMed ID: 32329362 [No Abstract] [Full Text] [Related]
12. Demonstration of Equivalence of Generic Glatiramer Acetate and Copaxone Lipsky P; Vallano PT; Smith J; Owens W; Snider D; Bandaru V; Sun Y; Wallingford R; Duncan J; Lewis J; Southall J; Ansari A; Li H Front Pharmacol; 2021; 12():760726. PubMed ID: 35002702 [TBL] [Abstract][Full Text] [Related]
13. [Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study]. Boyko AN; Lashch NY; Sharanova SN; Zakharova MN; Trifonova OV; Simaniv TO; Lysogorskaya EV; Guryanova OE; Kotov SV; Iakushina TI; Lizhdvoy VY; Belova YA; Khabirov FA; Babicheva NN; Khaibullin TI; Granatov EV; Averyanova LA; Sazonov DV; Odinak MM; Trinitatsky YV; Tsukurova LA; Sergeeva AI; Ivanov RA; Shustova MS Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):61-67. PubMed ID: 28139613 [TBL] [Abstract][Full Text] [Related]
14. Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis. Bourdette D; Hartung D JAMA Neurol; 2015 Dec; 72(12):1411-3. PubMed ID: 26457848 [No Abstract] [Full Text] [Related]
15. Comparison of Copaxone Arends RJ; Wang D; Buurman M; Luten J; Koper NP; Wolf C; Scheren M Pharmazie; 2019 Aug; 74(8):449-461. PubMed ID: 31526436 [TBL] [Abstract][Full Text] [Related]
16. Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results. Selmaj K; Barkhof F; Belova AN; Wolf C; van den Tweel ER; Oberyé JJ; Mulder R; Egging DF; Koper NP; Cohen JA; Mult Scler; 2017 Dec; 23(14):1909-1917. PubMed ID: 28090798 [TBL] [Abstract][Full Text] [Related]
17. [A place of first-line drugs in treatment of multiple sclerosis]. Kasatkin DS Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):145-151. PubMed ID: 28635741 [TBL] [Abstract][Full Text] [Related]
18. The influence of glatiramer acetate on Th17-immune response in multiple sclerosis. Melnikov M; Sharanova S; Sviridova A; Rogovskii V; Murugina N; Nikolaeva A; Dagil Y; Murugin V; Ospelnikova T; Boyko A; Pashenkov M PLoS One; 2020; 15(10):e0240305. PubMed ID: 33126239 [TBL] [Abstract][Full Text] [Related]
19. CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with Glatiramer Acetate (Copaxone). Losy J; Michałowska-Wender G; Kurdyńska A; Wender M Folia Neuropathol; 2005; 43(3):153-5. PubMed ID: 16245210 [TBL] [Abstract][Full Text] [Related]
20. Nicolau syndrome following glatiramer acetate for multiple sclerosis: Case and review of reports. Udawatta M; Mateen FJ Ann Clin Transl Neurol; 2024 Apr; 11(4):1080-1085. PubMed ID: 38483009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]